Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Who Should be Screened for Lung Cancer?
Videos
-
Lung Cancer
Edward Garon, MD
Dr. Edward Garon identifies the target population for lung cancer screening.
Related Items
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
published on
August 9, 2021
in
Conference Highlights ASCO
,
Lung Cancer
Patients with Lung Cancer Distressed About Impact of COVID-19 on Access to Care
Walter Alexander
Web Exclusives
published on
May 28, 2021
in
COVID-19
,
Lung Cancer
EGFR Most Common Mutation in Women with Lung Cancer and No Smoking History
Walter Alexander
Web Exclusives
published on
May 28, 2021
in
Lung Cancer
Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations
February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
published on
February 24, 2021
in
FDA Approvals
,
Lung Cancer
Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology
published on
August 17, 2020
in
Lung Cancer
Last modified: August 30, 2021